DICE Therapeutics, Inc.: M&A transaction — Eli Lilly completes acquisition of DICE Therapeutics for $48.00 per share; DICE now wholly owned subsidiary

each of Lisa Bowers, Dr. Mittie Doyle, Dr. Richard Scheller, Jim Scopa, Dr. Jake Simson and Sharon Tetlow resigned from his or her respective position as a member of the Company’s board of directors and all committees thereof, effective as of the Effective Time

each of Lisa Bowers, Dr. Mittie Doyle, Dr. Richard Scheller, Jim Scopa, Dr. Jake Simson and Sharon Tetlow resigned from his or her respective position as a member of the Company’s board of directors and all committees thereof, effective as of the Effective Time

Philip L. Johnson, Gordon J. Brooks and Michael C. Thompson, each a director of Purchaser immediately prior to the Effective Time, became directors of the Company, in each case, effective as of the Effective Time

The officers of Purchaser immediately prior to the Effective Time were Philip L. Johnson as President, Chris Anderson as Secretary, Michael C. Thompson as Treasurer, Jonathan Groff as Assistant Secretary and Katie Lodato as Assistant Treasurer.

each of Lisa Bowers, Dr. Mittie Doyle, Dr. Richard Scheller, Jim Scopa, Dr. Jake Simson and Sharon Tetlow resigned from his or her respective position as a member of the Company’s board of directors and all committees thereof, effective as of the Effective Time

The officers of Purchaser immediately prior to the Effective Time were Philip L. Johnson as President, Chris Anderson as Secretary, Michael C. Thompson as Treasurer, Jonathan Groff as Assistant Secretary and Katie Lodato as Assistant Treasurer.

each of Lisa Bowers, Dr. Mittie Doyle, Dr. Richard Scheller, Jim Scopa, Dr. Jake Simson and Sharon Tetlow resigned from his or her respective position as a member of the Company’s board of directors and all committees thereof, effective as of the Effective Time

each of Lisa Bowers, Dr. Mittie Doyle, Dr. Richard Scheller, Jim Scopa, Dr. Jake Simson and Sharon Tetlow resigned from his or her respective position as a member of the Company’s board of directors and all committees thereof, effective as of the Effective Time

Philip L. Johnson, Gordon J. Brooks and Michael C. Thompson, each a director of Purchaser immediately prior to the Effective Time, became directors of the Company, in each case, effective as of the Effective Time

Philip L. Johnson, Gordon J. Brooks and Michael C. Thompson, each a director of Purchaser immediately prior to the Effective Time, became directors of the Company, in each case, effective as of the Effective Time

The officers of Purchaser immediately prior to the Effective Time were Philip L. Johnson as President, Chris Anderson as Secretary, Michael C. Thompson as Treasurer, Jonathan Groff as Assistant Secretary and Katie Lodato as Assistant Treasurer.

each of Lisa Bowers, Dr. Mittie Doyle, Dr. Richard Scheller, Jim Scopa, Dr. Jake Simson and Sharon Tetlow resigned from his or her respective position as a member of the Company’s board of directors and all committees thereof, effective as of the Effective Time

The officers of Purchaser immediately prior to the Effective Time were Philip L. Johnson as President, Chris Anderson as Secretary, Michael C. Thompson as Treasurer, Jonathan Groff as Assistant Secretary and Katie Lodato as Assistant Treasurer.

The officers of Purchaser immediately prior to the Effective Time were Philip L. Johnson as President, Chris Anderson as Secretary, Michael C. Thompson as Treasurer, Jonathan Groff as Assistant Secretary and Katie Lodato as Assistant Treasurer.

the bylaws of the Purchaser became the bylaws of the Company, effective as of immediately following the Effective Time

the restated certificate of incorporation of the Company was amended and restated in its entirety, effective as of the Effective Time

to purchase all of the issued and outstanding shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at a purchase price of $48.00 per Share (the “ Offer Price ”), net to the stockholder in cash, without interest and less any applicable tax withholding. The Offer and related withdrawal rights expired as

the Amended and Restated Investors’ Rights Agreement entered into as of August 20, 2021 by and among the Company and the investors listed on Schedule A thereto terminated automatically in accordance with its terms

In addition, as previously disclosed, on April 15, 2023, the Company entered into an ATM Equity Offering SM Sales Agreement (the “ Sales Agreement ”), with BofA Securities, Inc. and Stifel, Nicolaus & Company, Incorporated (the “ Sales Agents ”) with respect to an “at-the-market” offering program under which the Company could offer and sell, from time to time, shares of its Common Stock through the Sales Agents.

Further, in connection with the closing of the Merger, effective as of August 9, 2023, the Company terminated its Loan and Security Agreement, dated as of April 13, 2021, as amended by that certain Joinder and First Amendment to Loan and Security Agreement, dated as of June 27, 2022 by and between Silicon Valley Bank (now a division of First-Citizens Bank & Trust Company), the Company and certain of the Company’s subsidiaries, as co-borrowers.